Exploratory study of WT-1 pulsed dendritic cell immunotherapy as a 2nd line treatment for patients with advanced/recurrent thymic carcinoma.
Not Applicable
Recruiting
- Conditions
- Thymic carcinoma
- Registration Number
- JPRN-UMIN000023543
- Lead Sponsor
- Fukushima Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with active concomitant malignancy 2) Patients have allergy for OK-432 or penicillin 3) With uncontrollable hypertension or diabetes 4) With angina pectoris or myocardial infarction 5) With uncontrollable heart failure or cerebrovascular disorder 6) With pulmonary fibrosis or interstitial pneumonia 7) With bleeding ulcer, intestinal obstruction 8) With Immunosuppressive agent or predonine 9) With severe allergy disease 10) With autoimmune disease 11) With myelodysplastic syndrome 12) Pregnancy or lactation. 13) Patients with mental disorder, and considered as inappropriate for the study by the physicians 14) Physician concludes that the patient's participation in this trial is inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method overall survival(OS), response rate, delayed type hypersensitivity, ELISPOT assay, tetramer assay